| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1009567244 |
| P356 | DOI | 10.2165/00003088-197904030-00001 |
| P698 | PubMed publication ID | 383353 |
| P2093 | author name string | A. Richens | |
| P2860 | cites work | Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients | Q72124686 |
| Depression of parahydroxylation of diphenylhydantoin by antituberculosis chemotherapy | Q72877695 | ||
| Studies on 5, 5'-diphenylhydantoin (dilantin) in animals and man | Q74303159 | ||
| DIPHENYLHYDANTOIN AND PHENOBARBITAL. SERUM LEVELS IN CHILDREN | Q76814827 | ||
| DIPHENYLHYDANTOIN AND PHENOBARBITAL TOXICITY. THE ROLE OF LIVER DISEASE | Q76935999 | ||
| A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments | Q77800417 | ||
| Studies on the metabolism of diphenylhydantoin (Dilantin) | Q79061537 | ||
| Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin | Q79177389 | ||
| Studies of anticonvulsant levels in epileptics. I. Serum diphenylhydantoin concentrations in a group of medically indigent outpatients | Q93789961 | ||
| Inhibition of phenytoin metabolism by sulthiame in epileptic patients | Q34451296 | ||
| Phenytoin dose adjustment in epileptic patients | Q34451359 | ||
| Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients | Q34451379 | ||
| Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding | Q34451491 | ||
| Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients | Q34451653 | ||
| Control of epilepsy with a single daily dose of phenytoin sodium | Q34451787 | ||
| Individual variation in daily dosage requirements for phenytoin sodium in patients with epilepsy | Q34516924 | ||
| Modification of phenytoin clearance by valproic acid in normal subjects | Q34518500 | ||
| Interactions with Antiepileptic Drugs | Q36493244 | ||
| The distribution of plasma phenytoin levels in epileptic patients | Q37070680 | ||
| Comparative evaluation of six techniques for determining the Michaelis-Menten parameters relating phenytoin dose and steady-state serum concentrations | Q39234330 | ||
| Serum-phenytoin levels in management of epilepsy | Q39334416 | ||
| Letter: Bioavailability of phenytoin | Q39367374 | ||
| Salivary phenytoin concentrations in epilepsy and in chronic renal failure | Q39467922 | ||
| Drug Kinetics in Pregnancy | Q39636007 | ||
| Loading and conventional dose therapy with phenytoin in children: Kinetic profile of parent drug and main metabolite in plasma | Q39771921 | ||
| Bioavailability of phenytoin: clinical pharmacokinetic and therapeutic implications | Q39798756 | ||
| Diphenylhydantoin metabolism. A prospective review | Q39873755 | ||
| Plasma Albumin Concentration and Diphenylhydantoin Binding in Man | Q40324415 | ||
| Pharmacokinetic approaches to the study of drug interactions | Q40646528 | ||
| Plasma Protein Binding of Phenytoin and Warfarin in Patients Undergoing Renal Transplantation1 | Q40771925 | ||
| Valproic acid in epilepsy: Clinical and pharmacological effects | Q40896491 | ||
| Plasma protein binding interaction between phenytoin and valproic acid in vitro | Q40975699 | ||
| Alteration of plasma albumin in relation to decreased drug binding in uremia | Q41280339 | ||
| Antiepileptic drugs: metabolism in pregnancy | Q41443340 | ||
| Anticonvulsant effect of diphenylhydantoin relative to plasma levels. A prospective three-year study in ambulant patients with generalized epileptic seizures | Q42231218 | ||
| Pharmacokinetics of a single dose of phenytoin in man measured by radioimmunoassay | Q43241864 | ||
| Phenytoin concentrations in mixed, parotid and submandibular saliva and serum measured by radioimmunoassay | Q43254024 | ||
| Diphenylhydantoin Metabolism in Uremia | Q43563484 | ||
| Diphenylhydantoin concentrations in saliva | Q43972399 | ||
| Interlaboratory Variability in Determination of Plasma Antiepileptic Drug Concentrations | Q44103631 | ||
| Bioavailability of three phenytoin preparations in healthy subjects and in epileptics | Q44665404 | ||
| Epilepsy and pregnancy: a study of 153 pregnancies in 59 patients | Q44669789 | ||
| Effects of Age, Sex, Obesity, and Pregnancy on Plasma Diphenylhydantoin Levels | Q68926969 | ||
| Variation in Response to Anticonvulsants in a Group of Epileptic Patients | Q69375981 | ||
| Single daily dose of diphenylhydantoin in children | Q69562271 | ||
| Inadequate serum levels after intramuscular administration of diphenylhydantoin | Q69578890 | ||
| Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy | Q69646920 | ||
| Diphenylhydantoin dosage | Q69688052 | ||
| Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin | Q69811428 | ||
| Dicoumarol-induced diphenylhydantoin intoxication | Q70066287 | ||
| Plasma protein binding of diphenylhydantoin in patients with epilepsy. Agreement between the unbound fraction in plasma and the concentration in the cerebrospinal fluid | Q70347852 | ||
| The Alteration of Plasma Proteins in Uremia as Reflected in their Ability to Bind Digitoxin and Diphenylhydantoin | Q70440093 | ||
| Diphenylhydantoin: Efficacy, toxicity, and dose-serum level relationships in children | Q70514951 | ||
| Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants | Q70560587 | ||
| Age differences in drug binding by plasma proteins: Studies on human foetuses, neonates and adults | Q70681355 | ||
| Outbreak of Anticonvulsant Intoxication in an Australian City | Q71582815 | ||
| Drug interaction: diazoxide and diphenylhydantoin | Q44948408 | ||
| Bioavailability of four brands of phenytoin tablets | Q45132697 | ||
| Assay of the major (4-hydroxylated) metabolites of diphenylhydantoin in human urine | Q45187322 | ||
| Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors | Q45286897 | ||
| The rate of decline of diphenylhydantoin in human plasma | Q46365064 | ||
| Diphenylhydantoin elimination kinetics in overdosed children | Q46920136 | ||
| Diphenylhydantoin binding by red blood cells of normal subjects | Q47827755 | ||
| Kinetics of diphenylhydantoin in uraemic patients: consequences of decreased plasma protein binding | Q47840215 | ||
| Erythrocyte uptake and plasma binding of diphenylhydantoin | Q47842173 | ||
| Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital | Q47853247 | ||
| Plasma protein binding of diphenylhydantoin. Effects of sex hormones, renal and hepatic disease | Q47886443 | ||
| Brain concentrations of phenytoin, phenobarbitone and primidone in epileptic patients | Q48435790 | ||
| Anticonvulsant drugs in human epileptogenic brain. Correlation of phenobarbital and diphenylhydantoin levels with plasma | Q48642253 | ||
| DIPHENYLHYDANTOIN METABOLISM, BLOOD LEVELS, AND TOXICITY. | Q52134645 | ||
| Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation | Q52439737 | ||
| Optimal phenytoin therapy: A new technique for individualizing dosage | Q52798861 | ||
| Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid | Q52847130 | ||
| The renal handling of diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin | Q53742927 | ||
| Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. | Q53755058 | ||
| Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied by mass fragmentography. | Q53864786 | ||
| Plasma diphenylhydantoin levels after loading and maintenance doses | Q53985812 | ||
| Increased Rate of Clearance of Drugs from the Circulation of Alcoholics* | Q54004788 | ||
| Intramuscular administration of diphenylhydantoin. Histologic follow-up studies. | Q54065624 | ||
| Serum Concentrations of Free Diphenylhydantoin and their Relationship To Clinical Intoxication | Q54312303 | ||
| Predicting Phenytoin Dose—A Revised Nomogram | Q54501926 | ||
| One Daily Dose of Diphenylhydantoin for Patients with Epilepsy | Q54766078 | ||
| Plasma Drug Level Monitoring in Pregnancy | Q67041229 | ||
| Plasma levels and protein binding of phenytoin during exercise in man: the effect of elevated free fatty acids | Q67245838 | ||
| Is phenytoin metabolism dose-dependent by enzyme saturation or by feedback inhibition? | Q67340381 | ||
| Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay | Q67353832 | ||
| Diphenylhydantoin, Phenobarbital, and Primidone in Saliva, Plasma, and Cerebrospinal Fluid | Q67380294 | ||
| Bioavailability of phenytoin. A comparison of two preparations | Q67431419 | ||
| Phenytoin: Pharmacokinetics and bioavailability | Q67443828 | ||
| Oral and intramuscular phenytoin | Q67478987 | ||
| Correlation between red cell and free plasma phenytoin levels in renal disease | Q67486499 | ||
| Absorption and metabolism of phenytoin from tablets and capsules | Q67496531 | ||
| Phenytoin and phenobarbitone plasma clearance during pregnancy | Q67524764 | ||
| Distribution of pentobarbital and diphenylhydantoin between plasma and cells in blood: effect of salicylic acid, temperature and total drug concentration | Q67541157 | ||
| Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults | Q67548903 | ||
| Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients | Q67548906 | ||
| Efficacy of intravenous phenytoin in the treatment of status epilepticus: kinetics of central nervous system penetration | Q67597978 | ||
| Plasma protein binding and metabolic clearance of phenytoin in the rat | Q67717238 | ||
| Decreased drug binding in serum from patients with chronic hepatic disease | Q67826138 | ||
| The elimination of phenytoin in man | Q67832201 | ||
| Lack of relationship between serum free fatty acids and impaired plasma protein binding of diphenylhydantoin in chronic renal failure | Q68210368 | ||
| Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy | Q68266365 | ||
| Plasma protein binding of diphenylhydantoin in man. Interaction with other drugs and the effect of temperature and plasma dilution | Q68749158 | ||
| A method for shifting from oral to intramuscular diphenylhydantoin administration | Q68786963 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 153-169 | |
| P577 | publication date | 1979-05-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Clinical Pharmacokinetics of Phenytoin | |
| P478 | volume | 4 |
| Q28367023 | A prolonged severe intoxication after ingestion of phenytoin and phenobarbital |
| Q69055468 | Absence of effect of cigarette smoking on serum concentrations of some anticonvulsants in epileptic patients |
| Q40142216 | Anticonvulsant drugs. An update |
| Q43299753 | Assessment of inter-individual variability in predicted phenytoin clearance |
| Q36966092 | Bioavailability and dissolution of proprietary and generic formulations of phenytoin |
| Q38513684 | CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects |
| Q71001938 | Chronic Anticonvulsive Therapy, Peripheral Nerve Conduction Velocity, and EMG |
| Q40087027 | Cimetidine as an Inhibitor of Drug Metabolism: Therapeutic Implications and Review of the Literature |
| Q36683160 | Clinical toxicology |
| Q37920931 | Clinically relevant anti-epileptic drug interactions |
| Q34403326 | Co-regulation of phenytoin and tolbutamide metabolism in humans |
| Q46304182 | Comparison of the effectiveness of two oral phenytoin products and chronopharmacokinetics of phenytoin |
| Q90285984 | Critical Care Management of Status Epilepticus at a Tertiary Care University Hospital |
| Q44095378 | Desloratadine demonstrates dose proportionality in healthy adults after single doses |
| Q74137827 | Determination of free levels of phenytoin in human plasma by liquid chromatography/tandem mass spectrometry |
| Q38756091 | Disposition of anticonvulsants in childhood |
| Q40153504 | Dose-Dependent Pharmacokinetics: Emphasis on Phase I Metabolism |
| Q34708717 | Drug Prescribing in Renal Failure: Dosing Guidelines for Adults |
| Q40167935 | Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations |
| Q72894693 | Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring |
| Q43651099 | Effect of temperature on serum protein binding characteristics of phenytoin in monotherapy paediatric patients with epilepsy |
| Q39548978 | Guide to drug dosage in renal failure |
| Q40884033 | Impact of generic substitution of anticonvulsants on the treatment of epilepsy |
| Q34596313 | Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients |
| Q38181565 | Implications of pharmacogenetics for the therapeutic use of antiepileptic drugs |
| Q71330535 | Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans |
| Q68329026 | Metronidazole Impairs Clearance of Phenytoin but Not of Alprazolam or Lorazepam |
| Q52692247 | Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. |
| Q41907962 | Pharmacokinetic investigation of the interaction of azapropazone with phenytoin |
| Q40307279 | Pharmacokinetics of drug overdose |
| Q37942243 | Pharmacokinetics of drug overdose. |
| Q34449678 | Pharmacokinetics of phenytoin in children |
| Q51620949 | Phenytoin and fasting. |
| Q40923025 | Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors |
| Q38164694 | Phenytoin removal by continuous venovenous hemofiltration |
| Q40164017 | Phenytoin: Basic and clinical pharmacology |
| Q34512209 | Plasma protein binding of phenytoin in 100 epileptic patients |
| Q36417519 | Population pharmacokinetics of phenytoin from routine clinical data in Japan |
| Q37713721 | Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles |
| Q39654030 | Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). |
| Q34622211 | Protein binding and CSF penetration of phenytoin following acute oral dosing in man. |
| Q35625069 | Rapid anticonvulsant monitoring in an epilepsy clinic |
| Q34398477 | Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects |
| Q52228230 | Serum protein binding kinetics of phenytoin in monotherapy patients. |
| Q52211022 | Temperature effect on serum protein binding kinetics of phenytoin in monotherapy patients with epilepsy. |
| Q52564191 | The assessment of bioavailability in the presence of nonlinear elimination. |
| Q42141493 | The effect of tenidap sodium on the disposition and plasma protein binding of phenytoin in healthy male volunteers |
| Q34123652 | The importance of drug interactions in epilepsy therapy |
| Q39658309 | The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation |
| Q37310486 | Therapeutic drug monitoring of phenytoin in critically ill patients |
| Q38018025 | Therapeutic drug monitoring of phenytoin. Rationale and current status |
| Q33828046 | Total Phenytoin concentration is not well correlated with active free drug in critically-ill head trauma patients |
| Q42088181 | Variations in the Blood Phenytoin Levels during Long-Term Combined Treatment with S-1 and Phenytoin. |
| Q34345819 | Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability. |
Search more.